| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2007.07.034 |
| P698 | PubMed publication ID | 17890079 |
| P50 | author | Giuseppe Giaccone | Q37829946 |
| P2093 | author name string | Christopher M Booth | |
| A Hilary Calvert | |||
| Elizabeth A Eisenhauer | |||
| Lesley K Seymour | |||
| Marinus W Lobbezoo | |||
| P433 | issue | 1 | |
| P304 | page(s) | 19-24 | |
| P577 | publication date | 2007-09-24 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) | |
| P478 | volume | 44 |
| Q43684447 | "Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents. |
| Q54569640 | Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer |
| Q35565672 | Advances in Statistical Approaches Oncology Drug Development |
| Q37222606 | Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? |
| Q92152744 | Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose |
| Q37723328 | Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents |
| Q33433456 | Current issues in oncology drug development, with a focus on Phase II trials |
| Q90493457 | Design and Conduct Considerations for First-in-Human Trials |
| Q39463857 | Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies |
| Q37198192 | Dose escalation methods in phase I cancer clinical trials |
| Q37270128 | Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities |
| Q33849805 | Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials |
| Q51819134 | Envisioning the future of early anticancer drug development |
| Q36238965 | How many diseases are colorectal cancer? |
| Q37822199 | Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction? |
| Q85498660 | Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials |
| Q40354212 | Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs |
| Q37152009 | Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. |
| Q38735014 | Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q33985780 | Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies |
| Q34440220 | Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors |
| Q92445960 | Phase I cancer clinical trials |
| Q33728406 | Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort |
| Q26865346 | Phase I trials of antitumour agents: fundamental concepts |
| Q47223679 | Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. |
| Q51640753 | Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials |
| Q47447457 | Proposal for size justification of expanded cohort at phase-2-recommended dose. |
| Q43140987 | Recommended changes to oncology clinical trial design: revolution or evolution? |
| Q38824605 | Sequential designs for individualized dosing in phase I cancer clinical trials |
Search more.